A program at the University of California San Diego designed to increase retention of underrepresented groups studying computer science will get a roughly $2 million boost from the National Science Foundation over the next five years.
Researchers at University of California School of Medicine are preparing to launch a novel clinical trial to examine the safety, efficacy and pharmacological properties of cannabis as a potential treatment for adults with essential tremor (ET). Currently, ET is treated using repurposed medications originally developed for high blood pressure or seizures.
On Saturday, October 6, hundreds of hackers are expected to descend upon the University of California San Diego campus to put their collaborative problem-solving capabilities to the test. The fast-paced, two-day event brings together interdisciplinary teams to identify and solve some of today’s most pressing health challenges, such as antibiotic resistance, opioid abuse and management of mental illness.
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have now identified three new molecular drug targets in Naegleria fowleri and a number of drugs that are able to inhibit the amoeba’s growth in a laboratory dish. Several of these drugs are already approved by the U.S. Food and Drug Administration for other uses, such as antifungal agents, the breast cancer drug tamoxifen and antidepressant Prozac.
The Nikon Imaging Center, a collaborative microscopy center that provides local researchers with access to the latest imaging technologies, opened September today at the University of California San Diego.
Researchers at University of California San Diego School of Medicine have discovered using mice and human clinical specimens, that caspase-2, a protein-cleaving enzyme, is a critical driver of non-alcoholic steatohepatitis (NASH), a chronic and aggressive liver condition. By identifying caspase-2’s critical role, they believe an inhibitor of this enzyme could provide an effective way to stop the pathogenic progression that leads to NASH — and possibly even reverse early symptoms.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
